Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

121. Aristada (aripiprazole lauroxil) - To treat adults with schizophrenia

Aristada (aripiprazole lauroxil) - To treat adults with schizophrenia Aristada (aripiprazole lauroxil) U.S. Department of Health and Human Services Search FDA Submit search Aristada (aripiprazole lauroxil) Aristada (aripiprazole lauroxil) Company: Alkermes, Inc. Application No.: 207533 Approval Date: October 5, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2015 FDA - Drug Approval Package

122. Causes and risk factors: Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia

Causes and risk factors: Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia Article Text

2015 Evidence-Based Mental Health

123. Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia

Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia Article Text Psychological interventions Sustained

2015 Evidence-Based Mental Health

124. Helping people with schizophrenia to quit smoking Full Text available with Trip Pro

). On the other hand, this review noted that there were no significant differences in schizophrenic or depressive symptoms between bupropion and placebo. In the included trials, as reported in the literature for bupropion in general, the drug was associated with insomnia, restlessness and dry mouth among others. You conclude that there is moderate quality evidence that bupropion would bring an important yet small benefit for people with schizophrenia who smoke but who would like to quit smoking. After some (...) Helping people with schizophrenia to quit smoking Helping people with schizophrenia to quit smoking | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search

2015 Evidence-Based Mental Health

125. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction

Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie (...) in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction Article Text Causes and risk factors Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D 2/3 receptor occupancy following risperidone and olanzapine dose reduction Hiroyoshi Takeuchi , Gary Remington Statistics from Altmetric.com ABSTRACT FROM: Graff-Guerrero A, Rajji TK, Mulsant BH, et al . Evaluation of antipsychotic

2015 Evidence-Based Mental Health

126. Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. (Abstract)

Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between antipsychotic drugs, however, low-potency antipsychotic drugs are sometimes perceived as less efficacious than high-potency compounds by clinicians, and they also seem to differ in their side effects.To review the effects in clinical response of flupenthixol and low-potency (...) antipsychotics for people with schizophrenia.We searched the Cochrane Schizophrenia Group Trials Register (July 2010).Randomised controlled trials that compared flupenthixol with first-generation low-potency antipsychotic drugs for people with schizophrenia or schizophrenia-like psychosis.We extracted data independently. For continuous data, we calculated mean differences (MD) based on a random-effects model.The review currently includes one randomised trial from mainland China with 153 participants

2014 Cochrane

127. Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia

Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia HAS - Medical, Economic and Public Health Assessment Division 1/16 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 19 February 2014 RISPERDAL 1 mg, scored film-coated tablet B/60 (CIP: 34009 338 948 7 0) RISPERDAL 2 mg, scored film-coated tablet B/60 (CIP (...) concerned National Health Insurance (French Social Security Code L.162-17) Hospital use (French Public Health Code L.5123 2) Indications concerned "RISPERDAL/RISPERDALORO is indicated for the treatment of schizophrenia." "RISPERDAL/RISPERDALORO is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorders." "RISPERDAL/RISPERDALORO is indicated for the short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from

2014 Haute Autorite de sante

128. Aripiprazole monohydrate (Abilify Maintena) - for the maintenance treatment of schizophrenia in adult patients stabilised with oral arip

Aripiprazole monohydrate (Abilify Maintena) - for the maintenance treatment of schizophrenia in adult patients stabilised with oral arip Final Appraisal Recommendation Advice No: 2214 – July 2014 Aripiprazole (Abilify Maintena ® ) 400 mg powder and solvent for prolonged release suspension for injection Submission by Otsuka Pharmaceuticals (UK) Ltd and Lundbeck Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (...) release suspension for injection is recommended as an option for use within NHS Wales for the maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

2014 All Wales Medicines Strategy Group

129. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Lurasidone (Latuda - Sunovion Pharmaceuticals (...) Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that lurasidone be listed for the management of the manifestations of schizophrenia if the following clinical criteria are met: 1. Patient has a contraindication to less expensive antipsychotic agents, or 2. Patient has failed a trial of less expensive antipsychotics because of intolerance

2014 Health Technology Assessment (HTA) Database.

130. Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation CADTH. Clinical review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Clinical Report. 2014 Authors' conclusions The main reason for the original CDEC recommendation of "Do Not List" was a lack of sufficient evidence to establish the comparative efficacy of lurasidone against other AAPs. In this updated review, no additional RCTs meeting the inclusion

2014 Health Technology Assessment (HTA) Database.

131. Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia

Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment (...) has been made for the HTA database. Citation CADTH. Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Recommendation - Pharmacoeconomic Report. 2014 Authors' conclusions At the submitted price of XXXXXX, lurasidone (XXXXXX per year) is less expensive than aripiprazole ($1,509 to $1,746 per year) and ziprasidone ($1,448 per year). Therefore, lurasidone would

2014 Health Technology Assessment (HTA) Database.

132. Horticultural therapy for schizophrenia. Full Text available with Trip Pro

Horticultural therapy for schizophrenia. Horticultural therapy is defined as the process of utilising fruits, vegetables, flowers and plants facilitated by a trained therapist or healthcare provider, to achieve specific treatment goals or to simply improve a person's well-being. It can be used for therapy or rehabilitation programs for cognitive, physical, social, emotional, and recreational benefits, thus improving the person's body, mind and spirit. Between 5% to 15% of people (...) with schizophrenia continue to experience symptoms in spite of medication, and may also develop undesirable adverse effects, horticultural therapy may be of value for these people.To evaluate the effects of horticultural therapy for people with schizophrenia or schizophrenia-like illnesses compared with standard care or other additional psychosocial interventions.We searched the Cochrane Schizophrenia Group Trials Register (Janurary 2013) and supplemented this by contacting relevant study authors, and manually

2014 Cochrane

133. Smoking cessation in patients with schizophrenia

Smoking cessation in patients with schizophrenia Smoking cessation in patients with schizophrenia Smoking cessation in patients with schizophrenia Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Smoking cessation in patients with schizophrenia. Lansdale: HAYES, Inc.. Directory Publication. 2014 Authors' conclusions The purpose of smoking cessation therapies (...) is to decrease smoking and smoking-related morbidity and mortality in patients. Interventions for smoking cessation may be pharmacologic and/or psychosocial. This report focuses on smoking cessation therapies in patients with schizophrenia. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Humans; Schizophrenia; Smoking Cessation Language Published English Country of organisation United States English summary An English language summary is available

2014 Health Technology Assessment (HTA) Database.

134. Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. (Abstract)

Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. Cognitive behavioural therapy for people with schizophrenia is a psychotherapeutic approach that establishes links between thoughts, emotions and behaviours and challenges dysfunctional thoughts. There is some evidence to suggest that cognitive behavioural therapy for people with psychosis (CBTp) might be an effective treatment for people with schizophrenia. There are however, limitations in its provision due (...) to available resource and training issues. One way to tackle this issue might be to offer a brief version of CBTp.To review the effects of brief CBTp (6 to 10 regular sessions given in less than 4 months and using a manual) for people with schizophrenia compared with standard CBTp (12 to 20 regular sessions given in 4 to 6 months and using a manual).We searched the Cochrane Schizophrenia Group's Trials Register (August 21, 2013) which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed

2014 Cochrane

135. Family intervention (brief) for schizophrenia. (Abstract)

Family intervention (brief) for schizophrenia. Supportive, positive family environments have been shown to improve outcomes for patients with schizophrenia in contrast with family environments that express high levels of criticism, hostility, or over-involvement, which have poorer outcomes and have more frequent relapses. Forms of psychosocial intervention, designed to promote positive environments and reduce these levels of expressed emotions within families, are now widely used.To assess (...) the effects of brief family interventions for people with schizophrenia or schizophrenia-like conditions.We searched the Cochrane Schizophrenia Group Trials Register (July 2012), which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. We inspected references of all identified studies for further trials. We contacted authors of trials for additional information.All relevant randomised studies that compared brief family-oriented psychosocial interventions with standard care, focusing

2014 Cochrane

136. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data Full Text available with Trip Pro

Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have (...) -effectiveness of lurasidone, compared with aripiprazole, for treating adult patients with schizophrenia, who had failed to respond to generic atypical antipsychotics. The authors concluded that lurasidone was less costly and more effective than aripiprazole. The results and modelling were well reported, but given the uncertainty around the use of all the best evidence available, the authors' conclusions may need to be interpreted with caution. Type of economic evaluation Cost-effectiveness analysis Study

2014 NHS Economic Evaluation Database.

137. Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia Full Text available with Trip Pro

Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia Jukic V, Jakovljevic M, Filipcic I, Herceg M, Silic A, Tomljanovic T, Zilbershtein R, Jensen RC, Hemels ME, Einarson TR Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of long-acting injectable paliperidone palmitate for people with stable chronic schizophrenia and a history of relapse and hospitalisation. The authors concluded that paliperidone was the most cost-effective long-acting injectable atypical

2014 NHS Economic Evaluation Database.

138. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Full Text available with Trip Pro

Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. Antipsychotic drugs are usually the first line of treatment for schizophrenia; however, many patients refuse or discontinue their pharmacological treatment. We aimed to establish whether cognitive therapy was effective in reducing psychiatric symptoms in people with schizophrenia spectrum disorders who had chosen not to take antipsychotic drugs.We did (...) a single-blind randomised controlled trial at two UK centres between Feb 15, 2010, and May 30, 2013. Participants aged 16-65 years with schizophrenia spectrum disorders, who had chosen not to take antipsychotic drugs for psychosis, were randomly assigned (1:1), by a computerised system with permuted block sizes of four or six, to receive cognitive therapy plus treatment as usual, or treatment as usual alone. Randomisation was stratified by study site. Outcome assessors were masked to group allocation

2014 Lancet Controlled trial quality: predicted high

139. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. Full Text available with Trip Pro

Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. It is estimated that more than half of those with serious mental illness smoke tobacco regularly. Standard courses of pharmacotherapeutic cessation aids improve short-term abstinence, but most who attain abstinence relapse rapidly after discontinuation of pharmacotherapy.To determine whether smokers diagnosed with schizophrenia and bipolar disease have (...) higher rates of prolonged tobacco abstinence with maintenance pharmacotherapy than with standard treatment.Randomized, double-blind, placebo-controlled, parallel-group, relapse-prevention clinical trial conducted in 10 community mental-health centers. Of 247 smokers with schizophrenia or bipolar disease recruited from March 2008-April 2012, 203 received 12-weeks' open-label varenicline and cognitive behavioral therapy and 87 met abstinence criteria to enter the relapse prevention

2014 JAMA Controlled trial quality: predicted high

140. Cognitive Adaptation Training for Schizophrenia

Cognitive Adaptation Training for Schizophrenia Cognitive Adaptation Training (CAT) for Schizophrenia – Society of Clinical Psychology Description Cognitive Adaptation Training (CAT) is designed to improve everyday functioning by teaching the individual with schizophrenia to use strategies that compensate for (or work around) the cognitive deficits associated with schizophrenia. Treatment plans are based on an assessment of the individual’s 1) level of apathy versus disinhibition and 2) level (...) and/or workplace. Key References (in reverse chronological order) Velligan , DI, Bow-Thomas, C.C., Huntzinger, C., Ledbetter, N., Prihoda, T.J., & Miller, A.L. (2000). Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. American Journal of Psychiatry, 157(8), 1317-1323. Velligan, D.I., Prihoda, T.J., Ritch, J.L., Maples, N., Bow-Thomas, C.C. & Dassori, A. (2002). A randomized single-blind pilot study of compensatory strategies

2014 Society of Clinical Psychology